Results 191 to 200 of about 98,405 (294)

A neuroendocrine approach to benzodiazepine tolerance and dependence. [PDF]

, 1981
Hannes Pétursson, Eric Shur, Sylvia Checkley, Alexandra Slade, M. Lader   +4 more
openalex   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Benzodiazepine or Antipsychotic Use and Mortality Risk Among Patients With Dementia in Hospice Care.

JAMA Netw Open
Gerlach LB, Zhang L, Kim HM, Teno J, Maust DT.   +4 more
europepmc   +1 more source

Adrenal Insufficiency During Treatment With Immune‐Checkpoint Inhibitors: How to Simplify the Diagnostic Pathway?

Clinical Endocrinology, EarlyView.
ABSTRACT Objective and Background Early identification of adrenal insufficiency (AI) during immune‐checkpoint inhibitors (ICIs) is crucial to prevent life‐threatening consequences; however, the diagnosis is challenging. Design, Patients and Measurement In this prospective observational study, ICI‐treated cancer patients with morning serum cortisol (SC)
Alice Nervo, Giovanni Gruosso, Marta Marino, Enrica Migliore, Matteo Rubiolo, Elisa Vaccaro, Emanuela Arvat   +6 more
wiley   +1 more source

Risks of prematurity and low birth weight associated with trimester-specific prenatal benzodiazepine exposure. [PDF]

J Psychiatry Neurosci
Chen VC, Chen YL, Kao KL, Lee YC, Lu ML, Wu SI, Stewart R.   +6 more
europepmc   +1 more source

A Scoping Review of the Emergence of Novel Synthetic Opioids in Australian Drug Markets: What Does This Mean for Harm Reduction Responses?

Drug and Alcohol Review, EarlyView.
ABSTRACT Issues Rising synthetic opioid deaths in North America, and the emergence of nitazene harms has driven concern about novel synthetic opioids (NSO) in Australia. This scoping review aimed to map what is known about NSOs in Australia. Approach Scoping review of peer‐reviewed and grey literature on NSO detections and harms.
Emmanuel Mammoliti, Suzanne Nielsen, Amanda Roxburgh   +2 more
wiley   +1 more source

Experiences of long-term benzodiazepine use and addiction amid changes in guidelines for the prescription of narcotic drugs: a qualitative study. [PDF]

BMC Public Health
Krüger C, Lindberg MH, Burmester S, Franck J, Westman J.   +4 more
europepmc   +1 more source

Emergence of Medetomidine in the Unregulated Drug Supply and Its Association With Hallucinogenic Effects

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction The unregulated drug supply in the United States is rapidly evolving, and veterinary tranquillisers have emerged as adulterants of concern, especially in illicitly‐manufactured fentanyl. Following the proliferation of xylazine, medetomidine, a more potent sedative, has recently appeared in multiple US states.
Adams L. Sibley, Madigan L. Bedard, Samuel Tobias, Brooke A. Chidgey, Irina G. Phillips, Alice Bell, Nabarun Dasgupta   +6 more
wiley   +1 more source

A Case Report of Continuous Flumazenil Infusion in a Nonagenarian With Benzodiazepine Toxicity, Managed Outside Intensive Care. [PDF]

Cureus
Romanello D, Pierini P, Brigato C, Cunego E, Rotunno S.   +4 more
europepmc   +1 more source

Synthesis of Heterocyclic Compounds Isosterically Related to Pyrazolo[4,3-c]quinolines as Benzodiazepine Receptor Ligands

, 1989
Hirohisa Shindo, Toshio Fujishita, Takashi Sasatani, Nobuo Chomei, Susumu Takada   +4 more
openalex   +1 more source